Pharvaris
PHVS
21 hedge funds and large institutions have $442M invested in Pharvaris in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 2 closing their positions.
154% more capital invested
Capital invested by funds: $174M → $442M (+$268M)
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
19.79% more ownership
Funds ownership: 65.71% → 85.49% (+20%)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
+$19.2M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
+$19.2M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$16.3M |
| 4 |
VA
VR Adviser
New York
|
+$12.8M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$4.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$3.48M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.84M |
| 3 |
Walleye Capital
New York
|
-$383K |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$48.4K |
| 5 |
Morgan Stanley
New York
|
-$35.3K |
PHVS Hedge Fund Activity: Q2 2023 in Review
21 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q2 2023, worth a combined $442M — up 154% from $174M a quarter earlier.
Fund positioning in PHVS was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 9 added to existing stakes and 4 trimmed.
The largest buyer was General Atlantic, adding an estimated $19.2M. The largest seller was Silverarc Capital Management, cutting an estimated $3.48M.
- 21 institutional investors held Pharvaris (PHVS) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $442M of Pharvaris stock for Q2 2023, up 154% quarter-over-quarter.
- 2 funds opened new Pharvaris positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest Pharvaris buyer in Q2 2023 was General Atlantic, an estimated $19.2M added.
- The largest Pharvaris seller in Q2 2023 was Silverarc Capital Management, an estimated $3.48M sold.
Based on aggregated 13F filings for Q2 2023.